A nonantisense sequence-selective effect of a phosphorothioate oligodeoxynucleotide directed against the epidermal growth factor receptor in A431 cells

Molecular Pharmacology

Volumn 50, Issue 2, 1996, Pages 314-325

  Coulson, Judy M ^a,c   Poyner, David R ^a   Chantry, Andrew ^b   Irwin, William J ^a   Akhtar, Saghir ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CANCER CELL; COMPETITIVE INHIBITION; DRUG EFFECT; GENE EXPRESSION; GENE TARGETING; GENETIC COMPLEMENTATION; GLIOBLASTOMA; IMMUNOBLOTTING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RIBOSOME;

BASE SEQUENCE; CELL DIVISION; CELLS, CULTURED; HUMANS; MOLECULAR SEQUENCE DATA; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; THIONUCLEOTIDES;

EID: 0029812567     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Wagner, R. Gene inhibition using antisense oligonucleotides. Nature (Lond.) 372:333-335 (1994).
2. Stein, C. A., and Y. C. Cheng. Antisense oligonucleotides as therapeutic agents: is the bullet really magical? Science (Washington D. C.) 261:1004-1012 (1993).
3. Stein, C. A., and A. M. Krieg. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res. Dev. 4:67-69 (1994).
4. Akhtar, S., R. Kole, and R. L. Juliano. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci. 49:1793-1801 (1991).
5. Agrawal, S., and S. Akhtar. Advances in antisense efficacy and delivery. Trends Biotechnol. 13:197-199 (1995)
6. Wong, A. J., P. W. Zoltlick, and D. K. Moscatello. The molecular biology and molecular genetics of astrocytic neoplasms. Semin. Oncol. 21:139-148 (1994).
7. Kung, H. J., C. M. Chang, and R. J. Pelley. Structural basis of oncogenic activation of epidermal growth factor receptor, in Biochemical and Molecular Aspects of Selected Cancers (T. G. Pretlow and T. P. Pretlow, eds.). Vol. 2. Academic Press, San Diego, 19-45 (1994).
8. Modjtahedi, H., and C. Dean. The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (Review). Int. J. Cancer 4:277-296 (1994).
9. Carpenter, G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 56:881-914 (1987).
10. Chantry, A. The kinase domain and membrane localisation determine intracellular interactions between epidermal growth factor receptors. J. Biol. Chem. 270:3068-3073 (1995).
11. Brown, P. M., M. T. Debanne, S. Groghe, D. Bergsma, M. Caron, C. Kay, O. Connor, and M. McCourt. The extracellular domain of the epidermal growth factor receptor: studies on the affinity and stoichiometry of binding, receptor dimerisation and a binding-domain mutant. Eur. J. Biochem. 225:223-233 (1994).
12. Khazaie, K., V. Schirrmacher, and R. B. Lichtner. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev. 12:255-274 (1993).
13. Ullrich, A., L. Coussens, J. S. Hayflick, T. J. Dull, A. Gray, A. W. Tam, J. Lee, Y. Yarden, T. A. Libermann, J. Schlessinger, J. Downward, E. L. V. Mayes, N. Whittle, M. D. Waterfield, and P. H. Seeburg. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (Lond.) 309: 418-425 (1984).
14. Kawamoto, T., J. D. Sato, A. Le, J. Polikoff, G. H. Sato, and J. Mendelsohn. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc. Natl. Acad. Sci. USA 80:1337-1341 (1983).
15. Devereux, J., P. Haeberli, and O. Smithies. A comprehensive set of sequence analysis programmes for the VAX. Nucleic Acids Res. 12:387-395 (1984).
16. Zuker, M. Computer prediction of RNA structure. Methods Enzymol. 180: 262-288 (1989).
17. Pearson, W. R., and D. J. Lipman. Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. USA 85:2444-2448 (1988).
18. Honegger, A. M., R. M. Kris, A. Ullrich, and J. Schlessinger. Evidence that autophosphorylation of solubilised receptors for epidermal growth factor is mediated by intermolecular cross-phosphorylation. Proc. Natl. Acad. Sci. USA 86:925-929 (1989).
19. Riedel, H., T. J. Dull, A. M. Honegger, J. Schlessinger, and A. Ullrich. Cytoplasmic domains determine signal specificity, cellular routing characteristics and influence ligand binding of epidermal growth-factor and insulin-receptors. EMBO J. 8:2943-2954 (1989).
20. Gorman, C. M., D. Gies, G. McCray, and M. Huang. The human cytomegalo-virus major immediate early promoter can be trans-activated by adenovirus early proteins. Virology 171:377-385 (1989).
21. Khan, I. M., and J. M. Coulson. A novel method to stabilise antisense oligonucleotides against exonuclease degradation. Nucleic Acids Res. 21: 2957-2958 (1993).
22. Yee, C., I. Krishnan-Hewlett, C. C. Baker, R. Schlegel, and P. M. Howley. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119:361-366 (1985).
23. Nister, M., C. Libermann, C. Bersholz, M. Pettersson, L. Claesson-Welsh, C. H. Heldin, J. Schlessinger, and B. Westermark. Expression of the messenger RNAs for platelet-derived growth factor and transforming growth factor-α and their receptors in human malignant glioma cell lines. Cancer Res. 48:3910-3918 (1988).
24. Jabbar, S. A. B., P. R. Twentyman, and J. V. Watson. The MTT assay underestimates the growth inhibitory effects of interferons. Br. J. Cancer 60:523-528 (1989).
25. King, A. C., R. A. Willis, and P. Cuatrecasas. Accumulation of epidermal growth factor within cells does not depend on receptor cycling. Biochem. Biophys. Res. Commun. 97:840-845 (1980).
26. Frank, R., and H. Koster. DNA chain length markers and the influence of base composition on electrophoretic mobility of oligodeoxyribonucleotides in polyacrylamide gels. Nucleic Acids Res. 6:2069-2087 (1979).
27. c-erbB-2 protooncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumour-cell proliferation. Cancer Gene Therapy 1:99-105 (1994).
28. Wang, S., R. J. Lee, G. Cauchon, D. G. Gorenstein, and P. S. Low. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA 92:3318-3322 (1995).
29. Okada, T., K. Yamaguchi, and J. Kamashita. Triplex-forming oligonucleotide binding represses transcription of the human c-erbB gene in glioma. Growth Factors 11:259-270 (1994).
30. Moroni, C. M., M. C. Willingham, and L. Beguinot. EGF-R antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J. Biol. Chem. 267:2714-2722 (1992).
31. Chakrabarty, S., S. Rajagopal, and S. Huang. Expression of antisense epidermal growth factor receptor RNA down-modulates the malignant behaviour of human colon cancer cells. Clin. Exp. Metastasis 13:191-195 (1995).
32. Akhtar, S., and R. L. Juliano. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol. 2:139-144 (1992)
33. Hudson, A. H., W. Lee, J. Porter, J. Akhtar, R. Duncan, and S. Akhtar. Stability of antisene oligonucleotides during incubation with a mixture of isolated lysosomal enzymes. Int. J. Pharm. (Amst.) 133:257-263 (1996).
34. Brice, E. C., J. X. Wu, R. Muraro, E. D. Adamson, and L. M. Wiley. Modulation of mouse preimplantation development by epidermal growth factor receptor antibodies, antisense RNA and deoxyoligonucleotides. Dev. Genet. 14:174-184 (1993).
35. Bennett, C. F. Intracellular delivery of oligonucleotides with cationic liposomes, in Delivery Strategies for Antisense Oligonucleotide Therapeutics (S. Akhtar, ed.). CRC Press, Boca Raton, 223-232 (1995).
36. bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res. 22:2150-2154 (1994).
37. Bergan, R., E. Kyle, Y. Connell, and L. Neckers. Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res. Dev. 5:33-38 (1995).
38. Tsiang, M., C. S. Gibbs, L. C. Griffin, K. E. Dunn, and L. L. K. Leung. Selection of a suppressor mutation that restores affinity of an oligonucleotide inhibitor for thrombin using in vitro genetics. J. Biol. Chem. 270: 19370-19376 (1995).
39. Wright, J. D., W. M. Reuter, and M. J. Weber. An incomplete program of cellular tyrosine phosphorylations induced by kinase defective epidermal growth factor receptors. J. Biol. Chem. 270:12085-12093 (1995).
40. 3 directly enhances serine phosphorylation of epidermal growth factor receptor, independently of receptor-receptor interaction. J. Biol. Chem. 269: 1959-1965 (1994).